Buscon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buscon

Property Description
Active Ingredient Hyoscine butylbromide
Pharmacological Class Antispasmodic Agent / Anticholinergic
Primary Forms Tablet, Injectable Solution
Origin Semisynthetic Belladonna Alkaloid Derivative
General Purpose Relieving smooth muscle spasms and cramping

Buscon is an antispasmodic agent whose active substance is the single chemical entity Hyoscine butylbromide (INN), formally designated as an anticholinergic drug and a muscarinic antagonist. The medication is widely clinically recognized for its capacity to interrupt the signals that cause painful contractions in the visceral organs. This compound is a semisynthetic derivative of hyoscine (scopolamine), which originates from the naturally occurring Belladonna alkaloid.

The drug is manufactured for both enteral and parenteral administration, commonly available as oral tablets and a sterile injectable solution supplied in ampoules, providing flexibility for acute or non-acute spasm management. As a single-ingredient pharmaceutical, its official classification and mechanism are detailed in pharmaceutical literature, confirming its primary role in relaxing smooth muscle tissues.

The general purpose of Buscon is to provide symptomatic relief by easing the severe, involuntary contractions known as visceral spasms. It achieves this by selectively blocking the nerve signals that cause the smooth muscle tissue in the internal organs to contract painfully. Due to its structure as a quaternary ammonium compound, the medication’s effects are highly restricted to the peripheral nervous system, ensuring its spasmolytic action is focused directly on the source of the discomfort within the gastrointestinal, biliary, and urogenital tracts.

What side effects are possible with Buscon?

Possible Side Effects and Safety Information

The safety profile of Buscon, whose active substance is Hyoscine butylbromide, is based on its documented peripheral anticholinergic properties, which define the nature of potential adverse reactions.

Adverse Reaction Scope Official Regulatory Documentation
Frequency-Classified Effects Common effects (affecting up to 1 in 10 users) include dry mouth, accommodation disorders (blurred vision), tachycardia (increased heart rate), dizziness, and constipation. Effects such as urinary retention are generally listed as Rare or Not Known (post-marketing).
System-Organ Classes Officially documented reactions are categorized in regulatory labels to primarily involve the Gastrointestinal tract, Cardiac system, Eye disorders, Skin and Immune system disorders.
Serious Adverse Reactions Regulatory documents explicitly list severe events, though rare, including anaphylactic shock (which may have a fatal outcome) and hypotension (low blood pressure), particularly following parenteral administration. Acute elevation of intraocular pressure (glaucoma) is also a documented risk in susceptible patients.
Population Safety Notes Particular caution is advised by regulatory agencies for patients with pre-existing cardiac conditions (e.g., heart failure, coronary heart disease, hypertension), as these individuals may be at risk for more severe cardiac adverse reactions from the medication.
Safety Restrictions Official prescribing information restricts the use of Buscon in conditions such as untreated narrow-angle glaucoma, prostatic hypertrophy with urinary retention, paralytic or obstructive ileus, mechanical stenosis of the gastrointestinal tract, and pre-existing tachycardia.

The official safety information structures the understanding of risks by categorizing adverse reactions based on their frequency and the physiological systems involved. These classifications, consistent with the standards of major regulatory authorities, define the boundaries of use and establish the risk profile, with a focus on anticholinergic-related effects and cardiovascular considerations.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Buscon (Hyoscine butylbromide) by detailing the expected cluster of peripheral anticholinergic manifestations. Overdosage is primarily characterized by the intensification of these effects, which include tachycardia (fast heart rate), dry mouth, reddening of the skin, urinary retention, and transient visual disturbances, such as accommodation disorders. Severe overdosage may lead to life-threatening outcomes, notably respiratory paralysis and severe cardiovascular instability.

Regulators mandate that immediate medical attention must be sought when specific severe symptoms are observed or if severe, unexplained abdominal pain persists or worsens alongside signs like fever, nausea, vomiting, or changes in blood pressure. Hospital observation and monitoring, particularly for patients with pre-existing cardiac conditions, may be required.

The regulatory-described management involves procedures such as gastric lavage for oral poisoning, and the administration of activated charcoal and Magnesium Sulphate. The effects of overdosage are officially documented as responding to parasympathomimetic agents, such as neostigmine, which may be administered to counteract the anticholinergic activity. Treatment must remain symptomatic and supportive, addressing any severe complications like respiratory paralysis through intubation and artificial respiration.

Therapeutic Uses of Buscon

Main Uses and Therapeutic Scope

Buscon is primarily utilized for the management of discomfort associated with spasms of the smooth muscles in the gastrointestinal, biliary, and genitourinary tracts. It belongs to a class of medications known as antispasmodics, which work by relaxing the muscles of the internal organs.

Gastrointestinal Conditions

The medication is frequently used to address symptoms related to functional disorders of the digestive system. This includes:

  • Abdominal Cramping: Relief of acute spasms in the stomach and intestines.
  • Irritable Bowel Syndrome (IBS): Management of the periodic cramping and abdominal pain often associated with this chronic condition.
  • General Digestive Discomfort: Alleviation of tension and pain caused by temporary muscle contractions in the digestive tract.

Biliary and Genitourinary Tracts

Beyond the digestive system, Buscon is applied to address spasms in other involuntary muscle systems:

  • Biliary Colic: Relief of spasms occurring in the bile ducts.
  • Genitourinary Spasms: Management of cramping in the urinary tract and bladder.
  • Menstrual Comfort: Relief of uterine contractions that lead to painful menstrual cramps (dysmenorrhea).

Benefits and Mechanism of Action

The primary benefit of Buscon is its targeted action on smooth muscle tissue. By inhibiting the action of acetylcholine on these muscles, the medication helps to reduce the frequency and intensity of contractions.

Key Therapeutic Advantages

  • Targeted Relief: It acts specifically on the site of the spasm rather than providing a generalized systemic effect.
  • Reduction of Tension: By facilitating muscle relaxation, it addresses the underlying cause of the pain rather than just masking the sensation.
  • Improved Functional Comfort: Relief from cramping often allows for improved comfort during daily activities and helps stabilize the rhythmic movements of the affected organs.

Regulatory References

  1. Health Canada Product Monograph for Buscopan

Eligibility and Restrictions for Use

Who Can and Cannot Use Buscon?

This section outlines the official population eligibility for Buscon (Hyoscine Butylbromide) as documented in regulatory government sources, including the EMA and FDA.

Eligibility Status Population or Condition
Allowed Adults and children mathbf6 years of age and over are permitted to use the oral tablets under labeled conditions.
Not Recommended The medicine is not recommended for children under 6 years of age. Use is also not recommended during pregnancy or lactation due to limited data and as a precautionary measure.
Contraindicated Myasthenia gravis, mechanical or obstructive gastrointestinal disorders (e.g., paralytic ileus, megacolon), prostatic hypertrophy with urinary retention, and untreated narrow angle glaucoma.

Specific Eligibility Constraints

Eligibility is constrained by formulation and route of administration. The injectable solution is explicitly contraindicated in patients with certain cardiac conditions, such as tachycardia or cardiac failure. Furthermore, injection into muscle (intramuscular route) is prohibited for individuals receiving anticoagulant drugs, although other routes may be permitted. Caution is advised in patients susceptible to intestinal or urinary outlet obstructions and in those prone to tachyarrhythmias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Hyoscine butylbromide (Buscon) focuses on pharmacodynamic and administrative interaction patterns, as documented by governmental health authorities.


Pharmacodynamic Interactions

Co-administration with other medicines that possess anticholinergic properties may result in an intensified anticholinergic effect. This applies to drug classes such as Tri- and Tetracyclic Antidepressants, Antihistamines, and certain Antipsychotics. Similarly, the tachycardic effects of Beta-Adrenergic Agents may be enhanced.

Conversely, concomitant treatment with Dopamine Antagonists (e.g., Metoclopramide, Domperidone) may result in a diminution of the effects of both medicines on gastrointestinal tract motility.


Administration-Route and Absorption Restrictions

Classification Restriction / Outcome
Parenteral Route The intramuscular injection is contraindicated in patients receiving Anticoagulant Drugs due to the specific risk of haematoma.
Altered Absorption The reduction in gastrointestinal motility may delay the systemic absorption and subsequent pharmacologic effects of other oral medications.

To prevent the reduction in Hyoscine butylbromide absorption, anticholinergics must be administered at least one hour before Antacids or Adsorbent Antidiarrheals. Alcohol consumption is officially advised against due to the risk of increased side effects.

Mechanism of Action

Buscon functions primarily as a selective allosteric modulator of the GABA A receptor complex, exhibiting high affinity for receptors containing the alpha1 and gamma2 subunit combination. The drug's molecular interaction occurs at a distinct regulatory site separate from the orthosteric binding site for the endogenous neurotransmitter GABA.

Binding of Buscon induces a conformational alteration within the receptor protein. This structural change modifies the GABA A receptor's response to GABA, resulting in potentiation—specifically, an increase in the frequency of the chloride ion (Cl^-) channel opening. This heightened channel activity leads to a significantly greater influx of negatively charged chloride ions across the postsynaptic neuronal membrane.

The resulting increase in intracellular Cl^- concentration causes hyperpolarization of the neuron, stabilizing the resting membrane potential and decreasing the cell's overall excitability. The mechanistic cascade culminates in a widespread increase in inhibitory neurotransmission within the central nervous system, thereby inducing a system-level physiological reduction in overall neuronal firing rates across interconnected neural circuits.

Dosage and Administration Information

How to Use Buscon

Buscon (hyoscine butylbromide) is used according to specific, officially labeled administration guidelines, defining the route, dosage, and frequency patterns for both oral and parenteral forms. The medicine is primarily intended for short-term, symptomatic relief and is explicitly not designated for continuous, long-term daily use without medical investigation.


Administration Routes and Dosing Regimens

The drug is supplied as 10 mg and 20 mg film-coated oral tablets and a 20 mg/mL solution for injection, allowing for flexible routes of administration.

Route of Administration Standard Adult Dose Maximum Daily Dose Frequency Pattern
Oral 10 mg to 20 mg per dose 80 mg Up to four times daily
Parenteral (IV, IM, SC) 20 mg per dose 100 mg May be repeated every 30 minutes

Use Conditions and Procedural Steps

For oral administration, tablets must be swallowed whole with water; they should not be crushed, broken, or chewed. Oral doses can generally be taken with or without food.

Parenteral administration requires the injectable solution to be administered slowly when using the intravenous (IV) route. The dose may be diluted with standard solutions like 0.9% sodium chloride. The intramuscular (IM) route is typically avoided in patients receiving anticoagulant therapy.

For the pediatric population, the oral dose is 10 mg three times daily for children over 6 years of age. The usage duration is confined to acute episodes, establishing the medicine as an episodic intervention within an overall treatment protocol.

Recent Clinical Evidence

Evidence for use in Relief of Abdominal Pain and Discomfort in Irritable Bowel Syndrome (IBS)

Buscon was studied for its application in settings involving the symptoms of Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating or episodic manifestations. The research examined patient-reported outcomes describing perceived discomfort and outcomes related to physical discomfort. Studies for this use were observed in clinical trials, relevant in trials assessing short-term or episodic symptom patterns.

The findings describe patterns observed in the studies related to changes in the intensity of outcomes related to physical discomfort during the study periods. While data show patterns related to these observations, these findings describe group patterns, not personal outcomes. Despite the evidence suggesting patterns of change, long-term effects are not fully established for this indication. The follow-up durations were limited in many trials, and comparative evidence is lacking for Buscon against other treatments.


Evidence for use in Treatment of Spasm associated with Biliary and Renal Colic

Buscon was evaluated in settings involving acute episodes, such as those associated with biliary (gallstone) and renal (kidney stone) colic. These are conditions associated with acute or disruptive episodes. The research explored its use specifically during episodes where symptoms become more noticeable, focusing on outcomes capturing phases of heightened symptom activity.

Studies conducted during periods of increased symptom activity examined whether Buscon was associated with a temporary change in patient-reported outcomes describing perceived discomfort. The research contributes to understanding symptom patterns about short-term symptom changes observed in emergency or inpatient settings. The results apply only to the populations studied, and data are still emerging regarding the overall role of Buscon in the management of these conditions.


What is Still Uncertain about Buscon

The research landscape for Buscon still contains areas that require further study. One area of uncertainty is that in some areas, findings were mixed across different trials. The lack of information regarding outcomes related to physical discomfort in certain subgroups and long-term use remains a constraint. Overall, studies help show what has been observed so far, but certainty remains low regarding its use across all possible clinical scenarios and patient types. The evidence highlights that more research is ongoing.

Key Studies & References

  1. Irritable bowel syndrome in adults: diagnosis and management - National Institute for Health and Care Excellence (NICE) Clinical Guideline
  2. Irritable Bowel Syndrome (IBS) - Merck Manual Professional Version (MSD Manuals)

Frequently Asked Questions (FAQ)

Common questions about Buscon (FAQ)


Q: Are there any common side effects of Buscon that usually go away?

Official product information indicates that the common side effects linked to the medication's mechanism of action are generally mild. They are expected to resolve over time and are typically transient, meaning they may diminish shortly after the medication's effect wears off or once the short course of treatment is completed.

Q: Does taking Buscon affect how birth control pills work?

Regulatory documents that list the known drug interactions for the active ingredient do not typically specify a direct interaction with hormonal contraceptive pills. However, because this medication can slow down movement in the digestive system, official leaflets contain instructions to inform a healthcare provider about all medicines taken.

Q: Does the time of day I take Buscon matter?

Official dosing guidelines focus primarily on the maximum frequency (e.g., up to four times daily), rather than a specific time of day. This indicates the medication is intended to be taken as needed and spaced out for symptomatic relief, rather than needing to be taken strictly at morning or night.

Q: Can Buscon affect my ability to drive or operate machinery?

Yes, official warnings advise caution. Because the medication may cause side effects like temporary blurred vision (accommodation disorder) or dizziness, official warnings state that driving or operating machinery should be avoided if these effects occur.

Q: What are the signs of an allergic reaction to Buscon?

Signs of a serious allergic reaction may include rash, hives, swelling of the face, lips, or tongue, and difficulty breathing (dyspnoea). The official safety profile explicitly lists severe hypersensitivity reactions and anaphylactic shock as potential adverse events, which represent a serious adverse event described in official documents.

Q: Why is the official name of Buscon different from the brand name?

The official name, Hyoscine butylbromide, is the standardized international chemical name for the active ingredient. Buscon is the brand or trade name that the pharmaceutical company assigns to market the product. This naming convention is standard practice for drug registration worldwide.

Q: Are there long-term side effects noted in regulatory reports for Buscon?

The medication’s intended use is limited to short-term, acute relief. Official regulatory guidance reflects this by advising against continuous use for long periods without investigation of the cause of the symptoms. Limited data exists regarding its use and safety over prolonged periods.

Q: Is it possible to be allergic to Buscon even on the first dose?

The medication is officially contraindicated (restricted from use) in patients with a known hypersensitivity or allergy to the active ingredient or any excipients (inactive ingredients). A potential for an allergic reaction is acknowledged in regulatory documents, consistent with the restriction on use in patients with known hypersensitivity.

Q: Why do some people say Buscon makes them feel tired?

While the medication is not commonly listed as causing fatigue, one of the common side effects listed in official documents is dizziness. This effect may contribute to a feeling of tiredness. Additionally, slight drowsiness has been reported in rare cases, particularly with the injectable solution.

Q: How long does it typically take for a person to notice the effect of Buscon?

According to official regulatory information, the medication is known to relieve smooth muscle spasm relatively rapidly. The onset of action is particularly quick when the medicine is administered via injection.

Q: If I miss a dose of Buscon, what generally happens?

Regulatory guidelines for this medication include specific instructions regarding missed doses, as they are part of the required administration information for patients. This guidance addresses how to proceed when a scheduled dose is forgotten and cautions against compensating for a forgotten dose.

Q: Is Buscon safe for elderly patients?

Official documentation contains a cautionary note regarding use in the elderly. Due to their higher sensitivity, older patients may be more susceptible to the anticholinergic side effects, which can include confusion, dry mouth, urinary retention, or constipation.

Q: Why is Buscon sometimes given to people who have [related but different condition]?

Official therapeutic indications state that the drug is used to relieve acute spasms in both the gastrointestinal tract and the genitourinary tract (such as with renal or biliary colic). Additionally, it is officially indicated for use as an antispasmodic during diagnostic procedures like radiology.

Q: What happens if a child accidentally takes Buscon?

The official documentation on overdosage states that signs can include exaggerated anticholinergic symptoms like a very fast heart rate (tachycardia), difficulty passing urine, and temporary visual disorders. Overdosage is described as a serious adverse event in official documentation.

Q: Is Buscon available over-the-counter in some countries?

The legal status of the medicine varies across countries, but in many major jurisdictions, it is classified as a Prescription Only Medicine (POM). This means the dispensing requires a prescription from a licensed healthcare provider.

Q: Do I need to change my activities while taking Buscon?

Official warnings cover activity changes if certain side effects occur. If you develop undesirable effects, such as dizziness or impaired vision, regulatory documents state that potentially hazardous activities like driving a car or operating heavy machinery should be avoided.

Q: Is it normal to feel a bit restless when starting Buscon?

Restlessness is not generally listed as a common adverse event in official documents. However, confusion or agitation has been reported in rare circumstances or in vulnerable individuals, such as the elderly, which might be perceived as restlessness.

Q: How quickly does Buscon leave the body after I stop taking it?

Pharmacokinetic data shows that the substance is quickly distributed to tissues after administration. The terminal elimination half-life is approximately 5 hours, meaning the body takes around that time to eliminate half of the remaining substance.

Q: Is Buscon a narcotic or controlled substance?

The medication is generally classified as a Prescription Only Medicine (POM) in most jurisdictions. It is not typically scheduled as a narcotic or controlled substance by government regulatory bodies.

Q: Are there any known drug interactions between Buscon and common pain relievers?

Official information lists classes of drugs that interact, such as certain antidepressants, antipsychotics, and antihistamines. The labeling includes general cautionary statements regarding the co-administration of drugs that share anticholinergic properties, as this can intensify effects.

Q: What is the purpose of the inactive ingredients in the Buscon pill?

Inactive ingredients, or excipients, are substances needed to form the tablet or solution but do not contribute to the main effect. Regulatory documents list these because some excipients, like lactose or sucrose, may be relevant to individuals with known intolerances or rare hereditary conditions.

Q: Can Buscon interact with herbal remedies or supplements?

Patient information leaflets contain instructions stating that a healthcare provider should be informed about all medicines being taken, including herbal medicines and dietary supplements. This is due to the potential for unlisted interactions that could affect how the drug works.

How should Buscon be stored and disposed of?

This section explains the official regulatory requirements for storing and disposing of Buscon (Hyoscine butylbromide), ensuring product integrity and safety.


Storage Requirements

Condition Requirement (Official Labeling)
Temperature & Light Store at or below 25 C or 30 C and protect from light and moisture.
Container Integrity Keep the medication in its original package. Ampoules are for single use; discard any unused contents immediately after opening.
Prohibited Areas Do not freeze the injectable solution. Avoid storing in damp places, such as a bathroom or near a sink.
Child Safety Keep out of the sight and reach of children (mandatory safety instruction).

Disposal Instructions

To dispose of unused or expired Buscon, return it to a pharmacist or follow local waste disposal regulations. Official guidance advises against flushing the medicine into sewer systems or water bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buscon found in:

A-Z Index: